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A B S T R A C T
Specific monitoring of cystatin C (CysC) levels in biological fluids is critical for diagnosis, treatment and me-
chanistic understanding of a spectrum of diseases, particularly chronic kidney disease (CKD). Despite evidences
that CysC correlates with the high risk and/or progression of CKD, its use in clinical practice is still scarce. In this
context, we report the development of a simple and sensitive immunosensor for the detection of CysC. The
biosensor combines the technology of cost-effective screen-printed electrodes with the high specificity of a
sandwich immunoassay. Optimized conditions showed that the sensor operates in a linear range between 10 and
100 ngmL−1, with a detection limit and a sensitivity of 6.0 ngmL−1 and 6.4 ± 0.3 μA ngmL−1 cm−2, re-
spectively. Moreover, the sensor provided precise results (RSD≤6.2%) and the quantification of CysC in CKD
serum samples revealed to be in agreement with the values obtained by a particle-enhanced nephelometric
immunoassay. In this light, the proposed immunosensor qualifies for clinical application, constituting a step
forward in the development of fast, sensitive and cost-effective diagnostic tools that can improve the current
medical care settings of CKD patients.
1. Introduction
Chronic Kidney Disease (CKD) is an enormous public health pro-
blem worldwide [1,2]. According to the Global Burden of Disease Study
(GBD), in 2015, kidney disease was the 12th most common cause of
death around the world with 1.1 million deaths (an increase of 32%
since 2005) [2,3]. Due to the increasing prevalence of conditions like
diabetes type 2 and hypertension [4–7] among the global population,
there has been an increase in the number of individuals affected by
CKD. One of the major concerns of CKD is the high prevalence of as-
sociated comorbidities and mortality. Most patients are often diagnosed
at advanced stages of CKD and may worsen due to complications re-
sulting from late medical intervention [8]. Moreover, CKD is also as-
sociated with a huge economic burden: in 2010, 2.62 million people
received dialysis worldwide and this fact is estimated to be double by
2030 [1,9,10]. Therefore, early diagnosis and timely intervention are
important to prevent disease progression.
There are several renal biomarkers that can be classified as
“traditional” and “novel”, although a number of the “novel” biomarkers
have been used for more than a decade [11]. Glomerular filtration rate
(GFR), a “traditional” one, remains as the most widely evaluated
parameter of kidney function. It is commonly used to quantify the rate
of progression in the vast majority of renal disorders as it estimates the
renal clearance in the glomeruli of a particular substance in a unit of
time [mL/min] [11,12]. However, since its measurement is time con-
suming and complex to perform in clinical practice, estimated GFR
(eGFR) equations are usually applied to monitor renal function decline.
Due to the ease of estimation, GFR readouts are normally based on
serum creatinine levels, which may not necessarily reflect a normal GFR
interval for a patient, since approximately 10–40% of urinary creatinine
is derived from tubular secretion and increases with the decline of
glomerular filtration [13]. There is, therefore, a weak relationship be-
tween renal function and serum creatinine at the early stages of CKD
until the secretory tubular process is saturated [14].
Among the several “novel” biomarkers (such as neutrophil gelati-
nase-associated lipocalin (NGAL) or kidney injury molecule-1 (KIM-1)),
CysC arises as a stronger marker than creatinine for detecting early
nephropathy [11,15]: unlike serum creatinine, CysC levels don't de-
pendent on age, gender or muscle weight of the individual [16–18], so
it's more reliable in the estimation of renal function. CysC is a 13-kDa
cysteine protease inhibitor produced by almost all nucleated cells pre-
sent in the body at a constant rate. Because of its low-molecular-weight,
CysC is freely filtered through the glomerular membrane and nearly
completely metabolized by the proximal tubular cells [19,20]. All these
properties render CysC as a better estimate of GFR, particularly to de-
tect minor GFR reductions, because the variation of creatinine rises
only when kidney function is already significantly impaired [17,21,22].
Epidemiologic studies have shown abnormal CysC levels (> 1mg/L) in
people with GFR<60mL/min/1.73m2, that can be used to classify
preclinical kidney disease [23,24]. Even though there are many evi-
dences that CysC can contribute to the improvement of the diagnosis of
CKD, with potential social and economic significance, its application to
clinical diagnosis remains scarce [25].
Several methods have been proposed for the determination of CysC,
with the most popular being particle-enhanced turbidimetric and ne-
phelometric immunoassays (PETIA and PENIA, respectively
[17,22,26]) and enzyme-linked immunosorbent assays (ELISA) [17,27].
Despite sensitive and rapid assays, the automated PETIA and PENIA
suffer from costly processes and specific immunoassay instrumentation,
which limit their usefulness in daily clinical routine. On the other hand,
requirements for relatively expensive test kits and bulky plate readers
limit ELISA's usefulness for point of care (POC) diagnostics. In addition
to these methods based on immunology, several commercial automated
or semi-automated analysers have also emerged in the market offering
multiplexed protein biomarker detection. Nevertheless, this type of
commercial equipment requires specialized personal and expensive
consumables, which again limits their use in health care units where
resources can be limited. Photoelectrochemical [28], fluorescence [29],
near-infrared spectrometry [30], and LC-MS-based proteomics [31]
have recently been reported as alternatives for the detection of CysC,
but all of them are currently too expensive and technically complex. As
an alternative to the above mentioned methods, electrochemical im-
munosensors, based on specific antigen-antibody interactions combined
with cost-effective, robust and miniaturized transducers, like screen-
printed electrodes (SPEs) [32–34], have become the most promising
approach to the labour intensive and time consuming assays that are
currently used for biomarker analysis [35–37]. Inherent advantages of
electrochemical sensors include simple sample pre-treatment proce-
dures, precise results, inexpensive instrumentation, low limits of de-
tection and short time-to-results for the analysis of proteins [38–40].
Moreover, the steps of the immunoassay can be carried out by using
small sample volumes (10–40 μL) directly on the transducer's surface,
which significantly lowers the consumption of expensive reagents,
comparatively to other classical methods. SPE-based biosensors are in
this way tuned with the growing need for performing rapid, inexpensive
and accurate in-situ analysis and for the development of point of care
portable devices [34].
The diagnostic significance of serum CysC in “modern diseases” is
beyond disputable and underlines the need for complementary la-
boratory tests in diagnosis, prognosis and availability of treatments that
can prevent health complications and significantly improve quality of
life. Nevertheless, to the best of our knowledge, an electrochemical
immunosensor devoted to the determination of CysC, comprising a
simple design, allowing possible integration in POC devices has not yet
been reported. In this work, we describe the development of a dis-
posable amperometric immunosensor that can detect CysC through a
sandwich-type assay. The design of a highly sensitive immunosensor
was achieved using a layer-by-layer construction approach employing
gold nanoparticles to generate an amplified response that can be easily
detected and measured. This immunosensor allows the determination of
CysC in human serum samples, obtaining results that are comparable to
those obtained by PENIA. The developed biosensor constitutes a
promising tool that can improve and complement the current clinical
exams for CKD, allowing an earlier intervention so that the treatment
might start when it is most effective.
2. Materials and methods
2.1. Reagents
The immunoreagents for CysC analysis were purchased from R&D
systems: anti-human-CysC mouse monoclonal antibody (anti-CysC;
capture antibody for CysC, Ab1), recombinant human CysC protein
(from mouse myeloma cell line) and anti-human-CysC mouse mono-
clonal biotinylated antibody (anti-CysC-bio; detection antibody for
CysC, Ab2). Analytical grade hydrochloric acid, magnesium nitrate
hexahydrate, nitric acid (≥35%), sodium chloride, tris(hydroxymethyl)
aminomethane, 3-indoxyl phosphate, β-casein from bovine milk and
streptavidin-alkaline phosphatase (S-AP) from Streptomyces avidinii
were all obtained from Sigma-Aldrich. Silver nitrate (≥99,9%) and
tetrachloroauric (III) acid (H[AuCl4]) were supplied by Alfa Aesar and
Merck, respectively.
2.2. Instrumentation and procedure
Linear sweep voltammetry (LSV) and the electrodeposition of gold
nanoparticles were performed using a potentiostat/galvanostat
(PGSTAT101, Metrohm Autolab), controlled by NOVA 1.10 software.
Carbon SPEs (SPCE) were obtained from DropSens (Spain) and pre-
sented a working electrode, with a diameter of 4.0mm, made of carbon
ink. The counter electrode was also made of carbon ink, whereas the
pseudoreference electrode was made of silver. All measurements were
performed, at least, in triplicate. Experiments were performed at
22 ± 1 °C. Scanning electron microscope (SEM) images were obtained
at the “Centro de Materias da Universidade do Porto” (CEMUP) using a
FEI QUANTA 400 FEG/EDAX Pegasus X4M equipment.
The immunoreagents for CysC were reconstituted following R&D
systems protocols, divided in aliquots and stored at −80 °C until used.
All immunoassay experiments were conducted using 0.1M Tris-HNO3
(pH 7.2), designated as buffer 1, except the 3-IP/Ag+ (1.0mM 3-IP and
0.4 mM AgNO3) solution which was prepared daily in a 0.1M Tris-
HNO3 (pH 9.8) containing 20mM MgNO3, referred throughout the text
as buffer 2. All solutions were prepared with deionized water
(resistivity= 18.2MΩcm, Millipore Simplicity 185).
2.3. SPCEs surface nanostructuration
Electrochemical generation of AuNPs has demonstrated to be a fast
method to obtain gold nanostructures in a reproducible way [41].
Briefly, the gold nanostructuration was performed by applying a con-
stant current of −100 μA for 240 s, followed by a constant potential
(0.1 V) for 120 s, using 40 μL of a 0.1-mM [AuCl4]– solution (in 0.1M
HCl) [41]. The resulting SPCE-AuNPs were rinsed and left to dry prior
to functionalization with Ab1. The morphology of the SPCE-AuNPs was
examined by SEM (ESI.1) and the particle size was estimated using
Image J software, as reported previously [42]. The AuNPs showed to be
uniformly distributed with an average diameter of 33.1 ± 15.4 nm.
2.4. Immunoassay procedure for CysC detection
After gold nanostructuration, the working electrode of the SPCEs
was functionalised as follows. Step 1: coating with capture antibody
(Ab1, 4 μgmL, 10 μL) followed by overnight incubation at 4 °C. The
excess and weakly adsorbed antibodies were removed by washing and
the free sites were blocked with casein (2% w/v, 40 μL, 30min). Step 2:
CysC standard solutions (40 μL of different concentrations) were in-
cubated for 60min. Step 3: incubation of a biotinylated anti-CysC de-
tection antibody solution (Ab2, 1 μgmL−1, 40 μL) for 60min. Step 4: the
tracer enzyme, AP, conjugated with streptavidin (S-AP), was added
(0.2 nM, 40 μL) and left to incubate for 60min. Step 5: the catalysis was
carried out by adding a 40-μL mixture of 3-IP (1mM) and silver nitrate
(0.4 mM), which was left to react for 20min in the dark. After this step,
voltammograms were recorded using LSV. The SPCEs were washed
after each step with buffer 1, except after step 4 where buffer 2 was
used.
2.5. Serum samples
Blood samples were collected from two CKD patients from the
Nephrology Service of the Hospital Centre of Porto. The Committee on
Ethics, from the Hospital Centre of Porto, approved the study protocol.
Patients participated in the study after informed and written consent,
respecting their privacy rights. Blood was collected by venepuncture
into tubes without anticoagulant, to obtain serum. Samples were pro-
cessed within 2 h of collection; aliquots of serum were prepared and
immediately stored at −80 °C until assayed.
The standard addition method was applied to determine CysC in
these samples. Prior to analysis, the samples were diluted (1:50) in
buffer 1 to achieve CysC levels within the linear range of the developed
immunosensor.
3. Results and discussion
3.1. Immunoassay optimization
A heterogeneous non-competitive immunoassay (sandwich-type
format) was adopted to develop a specific and sensitive immunosensor
for CysC detection. The used couple of matched monoclonal antibodies
were very selective for CysC (reducing nonspecific binding and cross-
reactions), thus determinant in the affinity of the antibody-antigen
binding. On the basis of the immunoassay format, the AuNPs-modified
SPCE was functionalised with capture antibody and the surface blocked
to minimise nonspecific adsorption. The sandwich immunocomplex was
formed after adding the protein and the biotinylated anti-CysC detec-
tion antibody. To trace the immunocomplex formation, the biotinylated
anti-CysC antibody was labelled with S-AP, which binds to it through
the strong non-covalent interaction biotin-streptavidin. The electro-
chemical signal was based on the re-oxidation of the enzymatically
generated metallic silver, Ag0: AP hydrolyses 3-IP resulting in an in-
doxyl intermediate that oxidises to indigo blue and reduces Ag+ present
in solution to Ag0 which is deposited on the electrode surface [43,44].
The AP-catalysed silver deposition reaction was detected through an
anodic voltammetric scan (from 0.0 V to + 0.4 V at 50 mV/s), where
the silver peak appears. The obtained peak current intensity is directly
proportional to the concentration of the antigen in the sample [43]. A
schematic representation of the sensor design and its working principle
can be seen in Fig. 1.
Several experimental variables that affect the immunosensor's per-
formance, such as the amount of (i) capture antibody, (ii) detection
antibody, (iii) enzymatic label and (iv) the incubation times were op-
timized.
3.1.1. Effect of AuNPs on the analytical signal
AuNPs are widely recognised to provide a suitable microenviron-
ment for biomolecule immobilization without distorting their bioac-
tivity [45]. They improve the electrochemical signal through a high
surface-to-volume ratio, contributing to an effective increase of the
amount of antibody immobilized on the surface, and thus enhancing the
sensor performance [41,46]. As expected, the nanostructured SPCE
enhanced the current intensity when compared to the unmodified SPCE
(ESI.2) Although for the blank the peak current also increased, the
signal-to-blank ratio when the SPCE-AuNP was employed is much
higher than for the bare SPCE, clearly improving the sensitivity of the
immunosensor. A shift of 100 ± 6mV in the oxidation peak potential,
towards less positive potentials, was also observed, showing that the
electron transfer is facilitated.
3.1.2. Optimization of capture and detection antibodies’ concentration
Three different concentrations of capture and detection antibodies,
in a total of 9 combinations, were tested as follows: capture antibody
solutions (concentrations tested: 2, 4 and 6 μgmL−1) were placed on
the SPCE-AuNPs and incubated overnight at 4 °C. Then, free surface
sites were blocked with casein and blank (0 ngmL−1) and CysC
(50 ngmL−1) solutions were incubated for 60min. Detection antibody
solutions (concentrations tested: 0.5, 1 and 2 μgmL−1) were cast on the
electrodes and left for 60min. An S-AP solution was placed on the
sensor and left to react for 60min. Finally, the sensor was washed with
buffer 2 and 40 μL of the substrate solution, a mixture of 3-IP/Ag+ (1.0
mM/0.4mM), was left to react during 20min. Voltammetric measure-
ments were subsequently performed, as indicated in Section 2.4. The
results of these optimisations are presented in Fig. 2A. The results of
assays 1, 2 and 3 were obtained using combinations of three different
concentrations of capture (2, 4 and 6 μgmL−1) and detection (0.5, 1
and 2 μgmL−1) antibodies in a total of 9 different combinations. The
peak current intensities increased in the presence of the CysC
(50 ngmL−1), compared to the blank signal (0 ngmL−1), proving that
the immunocomplex is formed. The peak current intensity (ip) increased
with the concentration of Ab1 up to 4 μgmL−1 (assays 1 and 2),
whereas 6 μgmL−1 (assay 3), the highest concentration of Ab1 tested,
revealed to be in excess, resulting in a poorer differentiation between
the blank and the CysC signal. Assay 2 (Ab1 4 μgmL and Ab2 0.5, 1 and
2 μgmL−1) yielded the best sensor performance showing the highest
signal-to-blank ratio. Among the three different concentrations (0.5, 1
and 2 μgmL−1) tested for Ab2, 1 μgmL−1 was the chosen concentration
for further studies since the blank signal had the lowest current in-
tensity and a better precision was obtained.
3.1.3. Optimization of S-AP concentration
The optimum amount of the enzymatic label was studied using two
different concentrations: 0.2 and 0.5 nM. The peak current for CysC
increased upon raising the S-AP concentration but an appreciable in-
crease in the background current (blank signal) was also observed,
which is probably due to the nonspecific adsorption of S-AP on the
electrode surface (Fig. 2B). A small amount of BSA (0.1%) was added to
the S-AP solution in separated tests to try to retain the CysC signal while
reducing the blank signal. It was observed that the addition of BSA
(assay 2′) was not effective in comparison with absence of BSA (assay
1′), as the current intensity for both the blank and CysC decreased si-
milarly, thus not improving the biosensor's performance (Fig. 2B). In
agreement with previous studies [47,48], an S-AP concentration of
Fig. 1. Schematic representation of the CysC immunosensor design and
working principle.
0.2 nM was then chosen as optimum and used for further studies.
3.1.4. Optimization of incubation time(s)
The sensor's construction and the analysis time was investigated
using different assay formats. This was done by combining different
assay steps and by pre-incubating the reagents during 30min before
placement on the sensor surface. The sensor's performance was eval-
uated using four different assays (Formats: W, X, Y and Z). The results
are presented in terms of current variation, Δip= ic−i0, (where ic is the
observed current at the set concentration of CysC and i0 is the blank
current), for an easier evaluation of the sensor performance (Fig. 3).
Format W: all the steps of the assay were performed sequentially and
separately as described in section 2.4; Format X: steps 2 and 3 were
combined (i.e. previous mixing of CysC and Ab2); Format Y: steps 3 and
4 were combined (i.e. previous mixing of Ab2 and S-AP); Format Z:
combination of steps 3, 4 and 5 (i.e. previous mixing of CysC, Ab2 and
S-AP).
As can be observed in Fig. 3, Format X, in which CysC and the anti-
CysC detection antibody were pre-incubated, provided the highest Δip.
A significant loss of current intensity is evident in Formats Y and Z. This
reduction in current intensity can be attributed to steric effects on the
affinity reactions characterised by a steric hindrance factor [49]. On the
other hand, the combination of steps 2 and 3 by pre-incubating CysC
and detection antibody, Format X, resulted in the optimal sensor per-
formance. This type of format favoured the immunocomplex formation,
which may be due to the antigen free binding sites being able to bind to
the captured antibody with minimal steric effects. As a result, Format X
was selected for further studies since it improves the sensor's design and
performance reducing the analysis time in 60min. In Table 1 a sum-
mary of the studied and selected variables is given.
3.2. Evaluation of the analytical performance of CysC immunosensor
In order to evaluate the analytical characteristics of the developed
immunosensor increasing concentrations of CysC were measured, under
the optimized experimental conditions (summarized in Table 1) and
assay Format X. The immunosensor was tested for CysC concentrations
up to 750 ngmL−1 (Fig. 4B). The peak current intensity showed a linear
relationship with the CysC concentration from 10 to 100 ngmL−1
(Fig. 4) with a determination coefficient of 0.994 according to the
following equation: ip (μA) = (0.803 ± 0.03)× [CysC] (ng
mL−1) + (15.09 ± 1.7). It is important to mention that all the metallic
silver was oxidised in the first scan because no signal was observed in
consecutive scans.
A detection limit of 6.0 ngmL−1 was obtained, calculated from the
concentration corresponding to the blank signal plus three times the
standard deviation. The sensitivity was found to be
6.4 ± 0.3 μA ngmL−1 cm−2, which was obtained from the slope of the
calibration curve divided by the geometrical area of the working
Fig. 2. Peak current intensities obtained by LSV for blank (0 ngmL−1) and CysC (50 ngmL−1), and the difference between them (Δip); A) different concentrations of
capture (Ab1: 2, 4 and 6 μgmL−1) and detection (Ab2: 0.5, 1 and 2 μgmL−1) antibodies; B) different S-AP (0.2 and 0.5 nM) concentrations, in the absence and
presence of 0.1% BSA. Other assay conditions: [S-AP]= 0.2 nM, [Casein]= 2% (w/v), [3-IP]= 1mM, [AgNO3]= 0.4mM. Results are presented as average ± SD
(n=3).
Fig. 3. Performance of the CysC sensor using different assay formats. Current
intensities, evaluated by LSV, represented as Δip= ic−i0. Experimental con-
ditions for all assays: Ab1 (4 μgmL−1); casein (2%); Ab2 (1 μgmL−1); S-AP
(0.2 nM); 3-IP (1mM) and silver nitrate (0.4 mM). Differences between assays:
(W) Addition of all immunoreagents in separated steps; (X) CysC and Ab2
previously mixed; (Y) Ab2 and S-AP previously mixed; and (Z) CysC, Ab2 and S-
AP previously mixed. Results are presented as average ± SD (n= 3).
Table 1
Optimization of the experimental variables of CysC immunosensor.
Variable Range tested Selected Value
Anti-CysC capture antibody concentration,
μg mL−1
2–6 4
Anti-CysC detection antibody concentration,
μg mL−1
0.5–2 1
S-AP concentration, nM 2–5 2
BSA concentration in S-AP solution, % (w/v) 0–0.1 0
electrode. The reproducibility of different sensors was evaluated
(RSD<6.2%, for 6 sensors measuring 50 ngmL−1 CysC), demon-
strating the potential of the immunosensor as a tool for direct appli-
cations in the point-of-care context.
3.3. Real sample analysis
To evaluate the immunosensor's performance from a clinical ap-
plication point of view, the concentration of CysC was determined in
CKD serum samples. As the typical CysC concentration in serum is
significantly higher than the highest concentration of the calibration
range, a dilution of the serum was carried out (1:50) in buffer 1. For
quantification purposes, and because matrix effects were observed, the
standard addition method was used, obtaining slopes of 1.7 ± 0.4 and
1.53 ± 0.07 μAmL ng−1 for samples A and B, respectively. The results
for the two samples showed to be in good agreement with those ob-
tained by the current gold standard PENIA (Table 2). This shows that
the developed immunosensor enables the detection of CysC in real
samples of CKD patients at an early stage of the disease (1 < CysC<
2mgmL−1) or mild decrease in the GFR, offering the advantages of
being cost-effective, simple and providing competitive sensitivity,
which is required for its use in clinical practice.
4. Conclusion
In the present work an electrochemical immunosensor, sandwich-
type format, based on SPCE modified with AuNPs, has been developed
for quantification of CysC. After optimization, the sensor, that requires
very low reagents and sample volumes (in the order of μL), showed
good precision and accuracy and a concentration range with clinical
utility. Moreover, the performance of the sensor for CysC quantification
in real serum samples was demonstrated.
The design of the developed sensor is economical and efficient when
compared with other current methods (e.g. PENIA) and furthermore,
the use of screen-printed electrodes provides the sensor with a huge
potential to be integrated in a PoC device with the aim of improving the
current clinical practice. Although the dilution step for sample analysis
is a limitation, which can be further improved, the developed biosensor
offers many advantages compared to other methods: simplicity, ease of
manufacture, rapid response, portability and no need of complex in-
strumentation or sample pre-treatment.
Therefore, the biosensor here described is a useful tool for simple
and decentralized CysC determination, contributing to improve the
early diagnosis of CKD and allowing an early treatment and the pre-
vention of the progression of the CKD.
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